total sale increas due new launch acquisit
maintain buy rate upgrad
tp estim tp base
forward price-to-earnings multipl adjust ep
expect forward price/sal
provid upsid potenti
expect growth revenu
estim base follow factor total
revenu growth strong growth across segment
acquisit made year new product
launch plan
total sale increas total
sale increas increas
due acquisit nxthera inc nxthera
claret medic inc claret augmenix
inc augmenix vertiflex inc vertiflex
prior period relat net sale
basic ep decreas decreas
dilut ep decreas
decreas net incom decreas
decreas
total world-wide revenu intervent cardiolog
busi increas
increas y/i increas
primarili driven sale boston scientif structur
valu replac outsid us sentinel cerebr
embol protect system purchas part claret
acquisit watchman left atrial appendag
compani name corpor tickerbsxstock ratingbuyunchangedindustri viewoverweightpositivepric oct week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth corporation| octob
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
total revenu endoscopi busi increas
increas
y/i increas primarili driven growth
compani biliari franchis spyglass ds
direct visual system axio stent
electrocauteri enhanc deliveri system hemostasi
franchis featur resolut clip infect
total revenu electrophysiolog busi increas
increas
y/i increas primarili driven global
expans boston scientif rhythmia map
product capit equip offer expand portfolio
navig enabl open-irrig cathet includ
compani blazer intellanav mifi open-irrig cathet
advanc diagnost cathet includ intellamap orion
announc close acquisit
vertiflex inc privately-held compani develop
commerci superion indirect decompress
minimally-invas devic use improv physic function
reduc pain patient lumbar spinal stenosi
receiv fda approv launch us
venou stent system treatment iliofemor venou
current price-to-earnings
price-to-earnings volatil past upward
trend averag price-to-earnings
expect forward price-to-earnings
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior dividend split forward annual dividend rate n/a forward annual dividend yield n/a trail annual dividend rate n/a trail annual dividend yield n/a year averag dividend yield n/a pay-out dividend date n/a ex-dividend date n/a last split factor new per last split date inform boston scientif corporation| octob
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement total gross research sale gener restructur oper total oper oper interest incom incom provis incom net incom continu net incom avail common weight averag share estim annual actual quarterli actual annual corporation| octob
equival short term invest trade asset secur total st invest receivablesaccount receiv total receiv current assetsinventori prepaid expens defer tax asset current restrict current asset total current asset long-term assetsgross properti plant equip accumul depreci properti plant equip long-term invest goodwil intang defer tax asset long-term asset total asset current liabilitiesaccount payabl accru expens short-term borrow current portion lt debt current liabil total current liabil long-term liabilitieslong-term debt def tax liabil non-curr capit leas non-curr liabil total liabil common equitycommon stock addit paid capit retain earn stock incom common equiti stockhold equitytot equiti liabil equitytot liabil equiti balanc sheet itemsactu annual actual quarterli corporation| octob
provid oper activ compar cash use
increas due one-tim settlement payment boston scientif
receiv edward lifesci corpor januari ir final net tax settlement
payment plu estim interest compani remit
use invest activ compar
includ payment acquisit busi net cash acquir relat
acquisit vertfllex milliped inc milliped purchas properti plant equip
payment invest acquisit certain technolog
provid financ activ increas compar
includ proce long-term borrow net debt issuanc cost
payment long-term borrow debt extinguish cost payment short-term
borrow net increas commerci paper
statement net incom oper activ depreci amort amort goodwil intang depreci amort total loss sale asset loss sale invest asset write-down restruc cost stock-bas compens oper activ chang account receiv chang inventori chang account payabl chang net oper asset oper invest activ capit expenditur sale properti plant equip acquisit divestitur invest market equiti securt invest activ invest financ activ short term debt issu long-term debt issu total debt issu short term debt repaid long-term debt repaid total debt repaid issuanc common stock repurchas common stock financ activ financ chang equival foreign exchang rate adjust miscellan adjust net chang boston scientif corporation| octob
report strong perform quarter due growth
across busi
total sale increas compar
increas includ oper net sale growth
neg impact basi point foreign currenc fluctuat
oper net sale includ approxim due
acquisit nxthera inc nxthera claret medic inc claret
augmenix inc augmenix vertiflex inc vertiflex
prior period relat net sale
total sale us increas compar
total sale emea europ middl east africa
increas compar
total sale apac asia-pacif increas
compar total sale latin america canada
increas compar
cog increas compar
gross profit increas compar
gross profit margin increas
compar
increas gross profit due posit impact cost reduct
result boston scientif process improv program
restructur program partial off-set unfavor product mix addit
foreign currenc fluctuat posit impact gross profit margin
sg expens increas compar
sg expens sale increas
compar increas due initi
relat recent acquisit compani focu key commerci
total sale increas
compar
gross profit increas
compar
 expens increas compar
 expens sale decreas
compar
compar
royalti expens remain flat compar
royalti expens sale decreas compar
amort expens compar
intang asset impair charg increas
compar conting consider expens
compar conting consider benefit
restructur charg compar
litigation-rel charg oper incom decreas
compar
interest expens compar
increas primarili due increas averag debt balanc follow
februari senior note offer portion proce februari
senior note offer intend use financ propos btg
net expens compar net incom
effect tax rate continu oper
compar
net incom decreas compar
basic ep decreas compar
dilut ep decreas compar
decreas
compar
total sale increas compar
increas includ oper net sale growth
neg impact basi point foreign currenc fluctuat
total sale increas
compar
oper net sale includ approxim due
acquisit nxthera inc nxthera claret medic inc claret
augmenix inc augmenix vertiflex inc vertiflex
prior period relat net sale
total sale us increas compar
total sale emea europ middl east africa
increas compar total sale
apac asia-pacif increas compar
total sale latin america canada increas
compar
cog increas compar
gross profit increas compar
gross profit margin remain flat
compar
gross profit increas
compar
sg expens increas compar
sg expens net sale remain flat
compar increas partial off-set
net gain record primarili associ portion edward
 expens increas compar
 expens sale
compar increas due invest across
compani busi recent acquisit order maintain pipelin
new product believ enhanc live patient world-wide
contribut profit sale growth
decreas expens sale attribut leverag
royalti expens decreas compar
decreas royalti expens relat expir royalti certain
countri amort expens increas
compar decreas due amortiz
intang asset acquir part boston scientif recent acquisit
intang asset impair charg increas compar
increas associ technology-rel
conting consider benefit compar
conting consider expens restructur charg
compar
litigation-rel charg includ gain
record repres portion total
one-tim settlement payment receiv edward lifesci corpor
compani record certain legal product liabil charg credit cost
defens consid unusu infrequ signific
litigation-rel net charg unaudit condens consolid financi
statement legal product liabil charg credit cost
record within sg expens portion relat gain
settlement record sg expens unaudit condens
consolid statement oper
compani continu assess certain litig claim determin
amount manag believ paid result claim
litig therefor addit loss may accru paid
futur could materi advers impact oper result cash flow
and/or compani abil compli debt coven
decreas
compar
charg
oper incom increas compar
interest expens compar
includ debt extinguish charg acceler
note offer subsequ repay exist senior note
termin bridg facil
net expens compar
compani recognis loss net
foreign currenc gain loss due chang fair valu contract
recognis earn contract settlement amount includ
acquisition-rel net charg credit present reconcili
result oper prepar accord us adjust
result consid manag
effect tax rate continu oper compar
decreas primarili relat impact certain
receipt charg tax differ rate effect tax rate
receipt charg includ intang asset impair charg
acquisition-rel item restructur item litigation-rel item well
certain discret tax item primarili relat share-bas payment
settlement compani transfer price disput intern revenu
servic ir tax year
net incom decreas compar
basic ep decreas compar
dilut ep decreas compar
increas
compar
decreas
compar
three report segment compris cardiovascular
rhythm manag medsurg repres aggreg
total revenu
increas
increas
total revenu
increas
increas
total revenu cardiovascular segment increas
compar total revenu increas
compar
oper incom increas compar
decreas compar
oper margin compar
compar
total world-wide revenu intervent cardiolog busi increas
compar
increas compar
total revenu increas
compar increas
compar
total intern revenu increas
compar increas
compar
increas revenu intervent cardiolog includ oper
net sale growth neg impact basi point
foreign currenc fluctuat compar y/i increas
primarili driven sale boston scientif structur heart therapi
includ acur transcathet aortic valu replac outsid us
sentinel cerebr embol protect system purchas part claret
acquisit watchman left atrial appendag closur laac
devic addit increas also driven sale complex
percutan coronari intervent pci product offer partial off-set
declin sale drug-elut coronari stent product offer
total revenu peripher intervent increas
compar increas
compar
total revenu increas
compar increas
compar total intern revenu
increas compar
increas compar
increas includ oper net sale growth neg
impact basi point foreign currenc fluctuat
compar y/i increas primarili driven drug-elut
technolog includ ranger drug-coat balloon eluvia drug elut
vascular stent system peripher angioplasti balloon technolog
intervent oncolog product solut well sale china
total revenu
cardiolog increas
increas
total revenu
increas
increas
total revenu medsurg segment increas
compar increas
compar
oper incom increas compar
increas compar
oper margin compar
compar
urolog pelvic health
total revenu urolog pelvic health busi increas
compar increas
compar
total revenu increas
compar increas
compar total intern revenu
increas compar
increas compar
increas includ oper net sale growth neg
impact basi point foreign currenc fluctuat
compar y/i increas primarili attribut growth
sale boston scientif prostat health product famili includ
spaceoar hydrogel system purchas part augmenix acquisit
rezum system purchas part nxthera acquisit
stone franchis includ lithovu digit flexibl
total revenu
increas
increas
total revenu
urolog pelvic
increas
increas
total revenu endoscopi busi increas
compar increas
compar
total revenu increas
compar increas
compar total intern revenu
increas compar
increas includ oper net sale growth neg
impact basi point foreign currenc fluctuat
compar y/i increas primarili driven growth
compani biliari franchis spyglass ds direct visual
axio stent electrocauteri enhanc deliveri
hemostasi franchis featur resolut clip infect
rhythm neuro
total revenu
increas
increas
total revenu
rhythm neuro
segment increas
increas
total revenu rhythm neuro segment increas
compar increas
compar
oper incom increas compar
increas compar
oper margin compar
compar
rhythm neuro
total revenu
busi increas
increas
total revenu electrophysiolog busi increas
compar increas
compar
total revenu remain flat compar
increas compar
total intern revenu increas
compar increas
compar
increas includ oper net sale growth neg
impact basi point foreign currenc fluctuat
compar y/i increas primarili driven global
expans boston scientif rhythmia map product
capit equip offer expand portfolio navig enabl open-
irrig cathet includ compani blazer intellanav mifi open-
irrig cathet advanc diagnost cathet includ intellamap
orion map cathet strong growth partial off-set softer
perform across portfolio core diagnost therapeut devic
particularli
total revenu neuromodul busi increas
compar increas
compar
total revenu remain flat compar
increas compar
total intern revenu increas
compar increas
compar
total revenu
busi increas
increas
total revenu
increas
rhythm neuro
increas includ oper net sale growth neg
impact basi point foreign currenc fluctuat
compar sale remain rel unchang y/i primarili due
weak spinal cord stimul system market well
compar strong sale signific growth
boston scientif launch spectra wavewrit partial
off-set strong global sale vercis deep brain stimul db system
total revenu cardiac rhythm manag increas
compar increas
compar
total revenu decreas
compar decreas
compar total intern revenu
increas compar
increas compar
increas includ oper net sale growth neg
impact basi point foreign currenc fluctuat
compar y/i increas primarili due global
strength boston scientif implant cardiovert defibril
cardiac resynchron therapi defibril crt-d subcutan
compani crt-d growth driven on-going global
commerci reson famili crt-d devic
includ heartlog heart failur hf diagnost increas s-icd sale
volum crt-d product replac cycl drive market share growth
strong defibril growth partial off-set declin pacemak
portfolio due share loss us result competit product
studi assess
safeti effect
acur
aortic valu system
intermedi high
indic
recent develop boston scientif pipelin
initi random studi assess safeti effect
acur aortic valv system intermedi high extreme-risk
patient indic transcathet aortic valv replac tavr result
trail expect serv basi compani pre-market
approv submiss drug administr fda
began global option trial studi patient non-valvular atrial
fibril undergo cardiac ablat procedur compar safeti
effect next-gener watchman flx left atrial appendag
closur laac devic first-lin oral anticoagul stroke risk reduct
announc close acquisit vertiflex inc privately-held
compani develop commerci superion indirect
decompress minimally-invas devic use improv physic
function reduc pain patient lumbar spinal stenosi
present two-year result intrepid random control trial
meet world societi stereotact function
neurosurgeri data demonstr safeti effect vercis
deep brain stimul db treatment patient
present real world data intern neuromodul societi world
congress chronic pain patient use spectra wavewrit spinal
cord stimul system result show two-third patient report
pain score two less last follow-up measur zero
announc acut result untouch studi emblem
subcutan implant defibril s-icd primari prevent
sudden cardiac death specif patient left ventricular eject
fraction lvef common popul indic
therapi data present heart rhythm societi annual scientif
session demonstr s-icd therapi complication-fre rate
day post-procedur high convers efficaci induc
ventricular fibril rate compar seen previou s-icd
recent develop boston scientif pipelin
commenc control launch europ lotu edg aoric
valv system minim invas tavr technolog patient sever
aortic stenosi consid high risk surgic valv replac via
receiv approv unit kingdom nation health servic
inclus spaceoar hydrogel innov technolog payment
program expand treatment access men undergo radiotherapi
receiv fda clearanc tactra next-gener malleabl penil
prosthesi first penil implant men erectil dysfunct
nitinol core optim rigid durabl conceal
receiv fda approv launch us venou stent
treatment iliofemor venou obstruct diseas
announc divestitur exist drug-elut bland
embol microspher portfolio varian medic system up-front cash
payment subject success complet compani
propos acquisit btg plc
launch us
venou stent
treatment
iliofemor venou
expect revenu growth rang
report basi expect revenu growth rang
organ basi
adjust ep expect rang
ep expect rang
growth
rang
increas
increas
boston scientif sale increas
increas basic ep decreas
basic ep decreas dilut ep decreas
dilut ep decreas
gross profit increas compar
increas compar
increas gross profit due posit impact
cost reduct result boston scientif process improv
program restructur program partial off-set unfavor product
margin
total revenu peripher intervent increas
increas y/i increas
primarili driven drug-elut technolog includ ranger drug-coat
balloon eluvia drug elut vascular stent system peripher angioplasti
balloon technolog intervent oncolog product solut well
sale china
total revenu urolog pelvic health busi increas
increas y/i
increas primarili attribut growth sale boston scientif
prostat health product famili includ spaceoar hydrogel system
purchas part augmenix acquisit rezum
purchas part nxthera acquisit stone
announc close acquisit vertiflex inc
privately-held compani develop commerci superion
indirect decompress minimally-invas devic use improv
physic function reduc pain patient lumbar spinal stenosi
receiv fda clearanc tactra next-gener malleabl penil
prosthesi first penil implant men erectil dysfunct
nitinol core optim rigid durabl conceal
non- reconcili
non- reconcili
non- reconcili
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
revenu growth ttm basi compar
gross margin ttm basi compar
net margin increas ttm basi compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth corporation| octob
mrqgross mrqnet mrqcog mrqsg mrqr sale boston scientif corporation| octob
inv flow
mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre mrqfinanci mrqreturn mrqreturn asset boston scientif corporation| octob
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset day sale day account day convers inventori cog inventori tax rate net incom net net margin annual itemsquarterli item boston scientif corporation| octob
balanc sheet item
outstand equival market debt common purchas properti plant sale properti plant equipment- purchas purchas sale issuanc net issuanc net chang capit free corporation| octob
current price-to-earnings price-to-earnings volatil past
upward trend averag price-to-earnings expect forward price-to-earnings
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdersharesd report outvaluefmr vanguard group inc capit world wellington manag compani jp morgan primecap manag bollard group top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard specialized-health vanguard/primecap growth fund america vanguard fund new perspect fund fundament investor fidel select portfolio medic technolog devic spdr etf trust fidel contrafund inc corporation| octob
develop close acquisit btg plc august today announc complet acquisit btg plc pursuant previous announc scheme arrang btg develop commerci product use minimally-invas procedur target cancer vascular diseas well specialti pharmaceut respond fda guidanc use peripher paclitaxel devic treatment padaugust food drug administr fda publish guidanc physician benefit-risk profil peripher paclitaxel devic intend treatment peripher arteri diseas pad guidanc note doctor discuss risk benefit avail pad treatment option may determin benefit paclitaxel devic outweigh risk late mortal individu high risk restenosi repeat intervent clinic work patient make inform treatment decis base avail data individu patient need close acquisit vertiflex incjun corpor today announc close acquisit vertiflex inc privately-held compani develop commerci superion indirect decompress minimally-invas devic use improv physic function reduc pain patient lumbar spinal stenosi lss narrow spinal canal caus compress nearbi nerv acquisit vertiflex add fda-approv commercially-avail minimally-invas interspin spacer industry-lead pain manag portfolio also includ spinal cord stimul radiofrequ ablat reciev fda approv venou stent may announc today food drug administr fda approv venou stent treatment iliofemor venou obstruct diseas occur flow blood vein locat deep pelvic region becom block blood clot compress anatom anomali venou obstruct diseas affect nearli popul caus condit deep vein thrombosi dvt post-thrombot syndrom pt compress diseas may-thurn syndrom patient venou obstruct blood may pool leg result pain swell skin ulcer corporation| octob
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
higher
compar
roa roi roe
respect ttm basi
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit corporation| octob
consensu view analyst trend stock
forecast lower
compar
 average
forward price-to-earnings
higher
compar
bsx avgfive-year growth forecast usdgrowth high day day day estim comparisonbsxindustri avg avgprice/earn yield corporation| octob
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim
averag revenu estim
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep last last daysn/an/an/an/adown last daysobsoleteobsoleteobsoleteobsoletedown last dayscurr growth ratescurr surprisescurr boston scientif corporation| octob
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
stock volatil quarter dip august
stock declin past
stock price volatil past current upward trend
rang stock gave return
stock price shown upward trend sinc past due growth busi
stock gave return past
deliv strong perform quarter due growth across segment geographi
recommend buy rate base perform recent acquisit strong pipelin
estim tp base forward price-to-earnings multipl
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
